Financing led by new investor Bain Capital with participation from new investor Wellington Management and all existing investors

由新投资者贝恩资本领投，新投资者惠灵顿管理公司和所有现有投资者跟投。

Proceeds to support advancement of ATSN-201 through potential approval and launch as well as preclinical programs to treat inherited retinal diseases

所得款项将用于支持ATSN-201的潜在批准和上市，以及治疗遗传性视网膜疾病的临床前项目。

Norbert Riedel, PhD, will join Atsena’s Board of Directors

诺伯特·里德尔博士将加入Atsena的董事会。

DURHAM, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics (“Atsena” or “the Company”), a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced the successful close of an oversubscribed $150 million Series C financing.

北卡罗来纳州达勒姆，2025年4月2日（环球新闻社）——Atsena Therapeutics（“Atsena”或“公司”），一家专注于通过基因药物的力量逆转或预防失明的临床阶段基因治疗公司，今天宣布成功完成了超额认购的1.5亿美元C轮融资。

The financing was led by Bain Capital’s Life Sciences team, with participation from an additional new investor, Wellington Management. All the Company’s existing investors also participated in the round, including Lightstone Ventures, Sofinnova Investments, Abingworth, Foundation Fighting Blindness, Hatteras Venture Partners, Osage University Partners, and the Manning Family Foundation..

本轮融资由贝恩资本生命科学团队领投，新投资者威灵顿管理公司也参与其中。公司所有现有投资者也都参与了本轮投资，包括Lightstone Ventures、Sofinnova Investments、Abingworth、Foundation Fighting Blindness、Hatteras Venture Partners、Osage University Partners以及Manning Family Foundation。

Proceeds from the financing will be used to advance Atsena’s lead program, ATSN-201, for the treatment of X-linked retinoschisis (XLRS), a genetic condition that is typically diagnosed in childhood and leads to blindness later in life. The proceeds will also support Atsena’s preclinical pipeline of first-in-class therapies and expand the use of Atsena’s novel spreading AAV.SPR capsid..

融资所得将用于推进Atsena的主导项目ATSN-201，该项目针对X连锁视网膜劈裂症（XLRS）的治疗，这是一种通常在儿童时期被诊断出的遗传病，并在成年后导致失明。所得资金还将支持Atsena的临床前首创新疗法管线，并拓展其新型扩散型AAV.SPR衣壳的应用。

“Closing our Series C marks a pivotal moment for Atsena as we advance our transformative ocular gene therapies and fuel our next phase of growth, innovation, and clinical progress,” said Patrick Ritschel, Chief Executive Officer of Atsena Therapeutics. “It follows a productive 12 months of key achievements including securing a partner to advance ATSN-101 to a global pivotal trial for Leber Congenital Amaurosis type 1 (LCA1) and initiating Part B of the ATSN-201 LIGHTHOUSE study for XLRS.

“关闭我们的C轮融资标志着Atsena的一个关键转折点，因为我们正在推进我们变革性的眼科基因疗法，并推动我们下一阶段的增长、创新和临床进展，” Atsena Therapeutics首席执行官Patrick Ritschel表示。“过去12个月是富有成效的，我们取得了多项关键成就，包括为ATSN-101找到合作伙伴，以推进针对Leber先天性黑蒙1型（LCA1）的全球关键试验，并启动了ATSN-201 LIGHTHOUSE研究的B部分，用于XLRS。”

We’re grateful for the support of our investors and partners who share our vision for the future of leveraging genetic medicine to reverse or prevent blindness.”.

“我们感谢与我们共享利用基因药物逆转或预防失明的未来愿景的投资者和合作伙伴的支持。”

To date, Atsena’s clinical portfolio has received multiple designations by the U.S. Food and Drug Administration (FDA). ATSN-101, for the treatment of LCA1, has received Rare Pediatric Disease designation, Orphan Drug Designation, and Regenerative Medicine Advanced Therapy designation. ATSN-201 has been granted Fast Track, Rare Pediatric Disease, and Orphan Drug Designations.

迄今为止，Atsena的临床产品组合已获得美国食品药品监督管理局（FDA）的多项认定。用于治疗LCA1的ATSN-101获得了罕见儿科疾病认定、孤儿药资格以及再生医学先进疗法认定。ATSN-201则被授予快速通道、罕见儿科疾病和孤儿药资格认定。

Updated data from the ongoing LIGHTHOUSE Phase I/II clinical trial evaluating ATSN-201 is anticipated later this year..

预计今年晚些时候将更新正在进行的LIGHTHOUSE I/II期临床试验评估ATSN-201的数据。

“We believe Atsena has a unique opportunity to deliver meaningful impact for patients with inherited retinal diseases on the basis of novel science and impressive clinical data generated to date,” said Amir Zamani, a Partner at Bain Capital. “We look forward to supporting Patrick and his strong team as they look to unlock the next phase of Atsena’s growth and innovation while thoughtfully advancing potentially groundbreaking therapies toward patients in need.”.

“我们相信，基于迄今为止产生的新颖科学和令人印象深刻的临床数据，Atsena 有独特的机会为遗传性视网膜疾病患者带来有意义的影响，”贝恩资本合伙人 Amir Zamani 表示。“我们期待支持 Patrick 和他强大的团队，因为他们希望开启 Atsena 下一阶段的增长与创新，同时深思熟虑地推进可能具有突破性的疗法，以帮助有需要的患者。”

In conjunction with the financing, Norbert Riedel, PhD, a seasoned scientist and biopharmaceutical executive, will join Atsena’s Board of Directors.

作为融资的一部分，资深科学家和生物制药高管诺伯特·里德尔博士将加入Atsena董事会。

Wedbush & Co. served as exclusive placement agent to Atsena for the Series C financing, Cooley LLP acted as its legal advisor.

Wedbush & Co. 担任了Atsena C轮融资的独家配售代理，Cooley LLP担任其法律顾问。

About Atsena Therapeutics

关于Atsena治疗公司

Atsena Therapeutics (“Atsena”) is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases. The company’s lead program is evaluating ATSN-201 in an ongoing Phase I/II clinical trial for X-linked retinoschisis (XLRS), a genetic condition that is typically diagnosed in childhood and leads to blindness later in life.

Atsena Therapeutics（“Atsena”）是一家临床阶段的基因治疗公司，致力于开发用于逆转或预防由遗传性视网膜疾病导致失明的一流治疗方法。该公司的主要项目正在评估ATSN-201，目前正在进行一项针对X连锁视网膜劈裂症（XLRS）的I/II期临床试验，这是一种通常在儿童时期被诊断出的遗传性疾病，并会在成年后导致失明。

ATSN-101, Atsena’s first-in-class, investigational gene therapy for Leber congenital amaurosis type 1 (LCA1) has completed a Phase 1 / 2 trial with positive results (.

ATSN-101，Atsena公司用于治疗Leber先天性黑蒙症1型（LCA1）的首创新基因疗法，已完成一期/二期试验，并取得积极结果。

https://doi.org/10.1016/s0140-6736(24)01447-8

https://doi.org/10.1016/s0140-6736(24)01447-8

). Atsena is advancing ATSN-101 toward the initiation of a global pivotal trial as part of its exclusive strategic collaboration with Nippon Shinyaku Co., Ltd. Atsena’s pipeline is powered by novel adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal diseases.

). Atsena正在推进ATSN-101，以启动其与日本新药株式会社（Nippon Shinyaku Co., Ltd.）独家战略合作的全球关键试验。Atsena的产品线依托新型腺相关病毒（AAV）技术，专门针对克服遗传性视网膜疾病带来的挑战而设计。

Founded by pioneers in ocular gene therapy, Atsena is led by an experienced team dedicated to addressing the needs of patients with vision loss. For more information, please visit .

Atsena 由眼部基因治疗领域的先驱创立，由一支经验丰富、致力于满足视力丧失患者需求的团队领导。欲了解更多信息，请访问。

https://atsenatx.com/

https://atsenatx.com/

.

。

Media Contact:

媒体联系人:

Gina Mangiaracina

吉娜·曼贾拉奇尼

6 Degrees

6度

(917) 797-7904

(917) 797-7904

gmangiaracina@6degreespr.com

gmangiaracina@6degreespr.com

Business Contact:

商务联系：

info@atsenatx.com

info@atsenatx.com